In this episode, we discuss Clene, a biopharmaceutical company making strides in treating neurodegenerative diseases like ALS and MS with their oral nanotherapeutic, CNM-Au8. CEO Rob Etherington shares trial results showing promise in increasing survival rates and improving outcomes for ALS patients, as well as enhancing vision, cognition, and neural function in MS. Clene's focus on mitochondrial health and neuron function is highlighted in the discussion.